Last reviewed · How we verify
Rosuvastatin-pantoprazole
This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole).
This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole). Used for Hypercholesterolemia with concurrent need for gastric acid suppression, Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy.
At a glance
| Generic name | Rosuvastatin-pantoprazole |
|---|---|
| Sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
| Drug class | Statin + proton pump inhibitor combination |
| Target | HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and cardiovascular risk. Pantoprazole is a proton pump inhibitor that suppresses gastric acid production, protecting the gastrointestinal tract. This fixed-dose combination addresses both lipid management and GI protection in patients at cardiovascular risk who may require acid suppression.
Approved indications
- Hypercholesterolemia with concurrent need for gastric acid suppression
- Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy
Common side effects
- Headache
- Myalgia
- Gastrointestinal upset
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults
- Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (PHASE4)
- Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: